Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium Difficile Infection in the United States

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2018 Jan 24

PMID 29360950

Citations 52

Authors

Dongmu Zhang

Vimalanand S Prabhu

Stephen W Marcella

Affiliations

Soon will be listed here.

Abstract

Background: The economic burden of Clostridium difficile infection (CDI), the leading cause of nosocomial infectious diarrhea, is not well understood. The objective of this study was to estimate the healthcare resource utilization (HCRU) and costs attributable to primary CDI and recurrent CDI (rCDI).

Methods: This is a database (MarketScan) study. Patients without CDI were matched 1:1 by propensity score to those with primary CDI but no recurrences to obtain HCRU and costs attributable to primary CDI. Patients with primary CDI but no recurrences were matched 1:1 by propensity score to those with primary CDI plus 1 recurrence in order to obtain HCRU and costs attributable to rCDI. Adjusted estimates for incremental cumulative hospitalized days and healthcare costs over a 6-month follow-up period were obtained by generalized linear models with a Poisson or gamma distribution and a log link. Bootstrapping was used to obtain 95% confidence intervals (CIs).

Results: A total of 55504 eligible CDI patients were identified. Approximately 25% of these CDI patients had rCDI. The cumulative hospitalized days attributable to primary CDI and rCDI over the 6-month follow-up period were 5.20 days (95% CI, 5.01-5.39) and 1.95 days (95% CI, 1.48-2.43), respectively. The healthcare costs attributable to primary CDI and rCDI over the 6-month follow-up period were $24205 (95% CI, $23436-$25013) and $10580 (95% CI, $8849-$12446), respectively.

Conclusions: The HCRU and costs attributable to primary CDI and rCDI are quite substantial. It is necessary to reduce the burden of CDI, especially rCDI.

Citing Articles

Clinical and economic outcomes associated with fidaxomicin in comparison to vancomycin, metronidazole, and FMT: A systematic literature review.

Li Q, Obi E, Marciniak A, Newman R, Whittle I, Kufakwaro J Medicine (Baltimore). 2025; 103(52):e39219.

PMID: 39969373 PMC: 11688082. DOI: 10.1097/MD.0000000000039219.

Incidence, healthcare and out-of-pocket costs, and mortality of infection among US adults aged 18 to 64 years.

Yu H, Alfred T, Zhou J, Judy J, Olsen M Antimicrob Steward Healthc Epidemiol. 2025; 4(1):e215.

PMID: 39758881 PMC: 11696600. DOI: 10.1017/ash.2024.400.

A quantitative PCR to detect non-toxigenic .

Begum K, Chua H, Alam M, Garey K, Jo J Microbiol Spectr. 2024; 13(1):e0160824.

PMID: 39660903 PMC: 11705841. DOI: 10.1128/spectrum.01608-24.

Comparison of the STANDARD M10 . , Xpert . , and BD MAX Cdiff assays as confirmatory tests in a two-step algorithm for diagnosing infection.

Choi H, Kang M, Yun S, Yu H, Suh E, Kim T Microbiol Spectr. 2024; 13(1):e0166224.

PMID: 39611822 PMC: 11705936. DOI: 10.1128/spectrum.01662-24.

Patient Satisfaction Scale Following a Laxative for Antibiotic Washout Prior to Oral Microbiome Therapy.

Chua H, Pham S, Lombardi D, Hot E, Mody L Adv Ther. 2024; 42(1):490-499.

PMID: 39607629 PMC: 11782395. DOI: 10.1007/s12325-024-03065-8.

References

Bignardi G . Risk factors for Clostridium difficile infection. J Hosp Infect. 1998; 40(1):1-15. DOI: 10.1016/s0195-6701(98)90019-6. View

Manning W, Mullahy J . Estimating log models: to transform or not to transform?. J Health Econ. 2001; 20(4):461-94. DOI: 10.1016/s0167-6296(01)00086-8. View

Vincent C, Miller M, Edens T, Mehrotra S, Dewar K, Manges A . Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection. Microbiome. 2016; 4:12. PMC: 4791782. DOI: 10.1186/s40168-016-0156-3. View

Johnson S . Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009; 58(6):403-10. DOI: 10.1016/j.jinf.2009.03.010. View

OBrien J, Lahue B, Caro J, Davidson D . The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol. 2007; 28(11):1219-27. DOI: 10.1086/522676. View

Gravel D, Miller M, Simor A, Taylor G, Gardam M, McGeer A . Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis. 2009; 48(5):568-76. DOI: 10.1086/596703. View

Lowy I, Molrine D, Leav B, Blair B, Baxter R, Gerding D . Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010; 362(3):197-205. DOI: 10.1056/NEJMoa0907635. View

Dubberke E, Butler A, Yokoe D, Mayer J, Hota B, Mangino J . Multicenter study of Clostridium difficile infection rates from 2000 to 2006. Infect Control Hosp Epidemiol. 2010; 31(10):1030-7. PMC: 3648217. DOI: 10.1086/656245. View

Zilberberg M, Shorr A, Kollef M . Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis. 2008; 14(6):929-31. PMC: 2600276. DOI: 10.3201/eid1406.071447. View

10.

Kelly C, Lamont J . Clostridium difficile--more difficult than ever. N Engl J Med. 2008; 359(18):1932-40. DOI: 10.1056/NEJMra0707500. View

11.

Ricciardi R, Rothenberger D, Madoff R, Baxter N . Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg. 2007; 142(7):624-31. DOI: 10.1001/archsurg.142.7.624. View

12.

Desai K, Gupta S, Dubberke E, Prabhu V, Browne C, Mast T . Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach. BMC Infect Dis. 2016; 16:303. PMC: 4912810. DOI: 10.1186/s12879-016-1610-3. View

13.

Kyne L, Hamel M, Polavaram R, Kelly C . Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002; 34(3):346-53. DOI: 10.1086/338260. View

14.

Heimann S, Vehreschild J, Cornely O, Wisplinghoff H, Hallek M, Goldbrunner R . Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital. Infection. 2015; 43(6):707-14. DOI: 10.1007/s15010-015-0810-x. View

15.

Loo V, Poirier L, Miller M, Oughton M, Libman M, Michaud S . A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005; 353(23):2442-9. DOI: 10.1056/NEJMoa051639. View

16.

McFarland L, Elmer G, Surawicz C . Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002; 97(7):1769-75. DOI: 10.1111/j.1572-0241.2002.05839.x. View

17.

Redelings M, Sorvillo F, Mascola L . Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis. 2008; 13(9):1417-9. PMC: 2857309. DOI: 10.3201/eid1309.061116. View

18.

Austin P . An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011; 46(3):399-424. PMC: 3144483. DOI: 10.1080/00273171.2011.568786. View

19.

Garey K, Sethi S, Yadav Y, DuPont H . Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008; 70(4):298-304. DOI: 10.1016/j.jhin.2008.08.012. View

20.

Campbell R, Dean B, Nathanson B, Haidar T, Strauss M, Thomas S . Length of stay and hospital costs among high-risk patients with hospital-origin Clostridium difficile-associated diarrhea. J Med Econ. 2013; 16(3):440-8. DOI: 10.3111/13696998.2013.770749. View